Multiple Myeloma Clinical Trial
Official title:
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
The main purpose of this study is to test the safety of dendritic cell tumor fusion study vaccine and to determine the type and severity of any side effects associated with this study vaccine. Cancer cells have unique markers that distinguish them from normal cells of the body. These markers can potentially serve as targets for the immune system. Dendritic cells are normally found in small amounts in the body and are responsible for immune responses against "foreign" substances that enter the body. Animal studies have shown that these fused cells can stimulate powerful anti-tumor responses.
- To create the study vaccine, cells will be removed from the participants tumor and
fused (mixed) with powerful immune system stimulating cells (dendritic cells) obtained
from the participants blood.
- Not everyone who participates in this study will be receiving the same amount of study
vaccine. A small group of people will be enrolled into the study and given a certain
dose. If they tolerate it well, the next group of people enrolled will receive a higher
dose. This will continue until the highest dose level tolerated is determined.
- Once the screening tests are completed and it is determined the participant is
eligible, they will undergo some baseline procedures. In an effort to make the study
vaccine, tumor cells and dendritic cells will be collected from the participant. Tumor
cells may be collected from bone marrow or from a collection of tumor cells called a
plasmacytoma. A decision will be made based upon the location of the cancer.
- A bone marrow aspiration/biopsy will be performed during the following time points: at
screening, prior to the first vaccination, and at 1 month, 3 months, and 6 months after
the final study vaccination. These will be used to assess and follow the participants
multiple myeloma.
- Leukapheresis will be performed to obtain dendritic cells. This procedure takes 2 to 4
hours to and involves the collection of a large number of white blood cells. Dendritic
cells will be generated in the laboratory from white blood cells. If not enough white
blood cells are collected, the participant may be asked to return to the clinic for an
additional leukapheresis procedure.
- Before each vaccine is administered (weeks 0, 3, 6) the following study tests and
procedures will be performed: skin test; blood test, physical exam and 24-hour urine
collection. A physical exam and blood tests will be performed on the weeks when the
participant does not receive the vaccine (weeks 1,2,4,5,7,8).
- The study schedule will consist of a fixed dose of the fused (mixed) cell vaccine under
the skin every 3 weeks. Each study vaccine will be accompanied by an injection of
GM-CSF. Participants will receive 2 or more vaccines depending upon the total number of
fusion cells made, the dose the participant is assigned to receive and their response
to the study vaccine.
- Follow-up after the vaccine treatment is completed will consist of the following: blood
collection (1, 3 and 6 months after final study vaccination); bone marrow
aspiration/biopsy (1, 3 and 6 months after final study vaccination); physical exam (1,
2, 3, 4, 5 and 6 months after final study vaccination); radiologic tumor assessment (1,
3 and 6 months after final study vaccination.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |